NASDAQ:ANAB AnaptysBio Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AnaptysBio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.09 +0.28 (+1.77 %) (As of 09/18/2020 03:21 PM ET) Add Compare Share Today's Range$15.61Now: $16.09▼$16.1850-Day Range$14.44MA: $16.99▼$18.6652-Week Range$10.00Now: $16.09▼$44.99Volume11,419 shsAverage Volume421,157 shsMarket Capitalization$439.32 millionP/E RatioN/ADividend YieldN/ABeta0.72 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 0.9 Analyst's Opinion Consensus RatingAnaptysBio has received a consensus rating of Hold. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.20, AnaptysBio has a forecasted downside of 5.5% from its current price of $16.09.Amount of Analyst CoverageAnaptysBio has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAnaptysBio has received 322 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnaptysBio has received 250 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnaptysBio has received 56.29% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote “Outperform” if you believe ANAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.00% of the stock of AnaptysBio is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AnaptysBio are expected to decrease in the coming year, from ($2.05) to ($2.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.9Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANAB Previous Symbol CUSIPN/A CIK1370053 Webwww.anaptysbio.com Phone858-362-6295Debt Debt-to-Equity RatioN/A Current Ratio19.10 Quick Ratio19.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8 million Price / Sales54.92 Cash FlowN/A Price / Cash FlowN/A Book Value$14.93 per share Price / Book1.08Profitability EPS (Most Recent Fiscal Year)($3.60) Net Income$-97,340,000.00 Net MarginsN/A Return on Equity-20.18% Return on Assets-18.94%Miscellaneous Employees78 Outstanding Shares27,304,000Market Cap$439.32 million Next Earnings Date11/13/2020 (Estimated) OptionableOptionable $16.09 +0.28 (+1.77 %) (As of 09/18/2020 03:21 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ANAB News and Ratings via Email Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions How has AnaptysBio's stock been impacted by Coronavirus? AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANAB stock has increased by 4.5% and is now trading at $15.92. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of AnaptysBio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AnaptysBio. When is AnaptysBio's next earnings date? AnaptysBio is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for AnaptysBio. How were AnaptysBio's earnings last quarter? AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.04. View AnaptysBio's earnings history. What price target have analysts set for ANAB? 7 brokerages have issued 12-month target prices for AnaptysBio's shares. Their forecasts range from $12.00 to $17.00. On average, they anticipate AnaptysBio's share price to reach $15.20 in the next year. This suggests that the stock has a possible downside of 4.5%. View analysts' price targets for AnaptysBio. Are investors shorting AnaptysBio? AnaptysBio saw a decrease in short interest in June. As of June 30th, there was short interest totaling 5,120,000 shares, a decrease of 12.0% from the June 15th total of 5,820,000 shares. Based on an average daily volume of 383,300 shares, the short-interest ratio is currently 13.4 days. Approximately 20.6% of the company's stock are sold short. View AnaptysBio's Short Interest. Who are some of AnaptysBio's key competitors? Some companies that are related to AnaptysBio include MacroGenics (MGNX), Kura Oncology (KURA), Mersana Therapeutics (MRSN), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK), Ligand Pharmaceuticals (LGND), Heron Therapeutics (HRTX), ZEALAND PHARMA/S (ZEAL), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Intercept Pharmaceuticals (ICPT), ALX Oncology (ALXO) and Generation Bio (GBIO). View all competitors. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include ImmunoGen (IMGN), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Amarin (AMRN), bluebird bio (BLUE), Editas Medicine (EDIT), Clovis Oncology (CLVS), Illumina (ILMN), Twilio (TWLO) and Appian (APPN). Who are AnaptysBio's key executives? AnaptysBio's management team includes the following people: Mr. Hamza Suria, Pres, CEO & Director (Age 43)Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)Prof. Marco Londei, Chief Medical Officer (Age 62)Mr. Eric J. Loumeau, Gen. Counsel (Age 56)Dr. Hemant Kumar, Sr. VP of Manufacturing When did AnaptysBio IPO? (ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is AnaptysBio's stock symbol? AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB." Who are AnaptysBio's major shareholders? AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.26%), Federated Hermes Inc. (5.19%), BVF Inc. IL (4.74%), Cormorant Asset Management LP (3.24%), Two Sigma Advisers LP (1.50%) and Goldman Sachs Group Inc. (1.26%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria and Marco Londei. View institutional ownership trends for AnaptysBio. Which major investors are selling AnaptysBio stock? ANAB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Krensavage Asset Management LLC, Cormorant Asset Management LP, Bank of America Corp DE, Vanguard Group Inc., State Board of Administration of Florida Retirement System, PDT Partners LLC, and Engineers Gate Manager LP. View insider buying and selling activity for AnaptysBio. Which major investors are buying AnaptysBio stock? ANAB stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Point72 Asset Management L.P., Federated Hermes Inc., FMR LLC, FMR LLC, Globeflex Capital L P, Alps Advisors Inc., and Jacobs Levy Equity Management Inc.. View insider buying and selling activity for AnaptysBio. How do I buy shares of AnaptysBio? Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AnaptysBio's stock price today? One share of ANAB stock can currently be purchased for approximately $15.92. How big of a company is AnaptysBio? AnaptysBio has a market capitalization of $434.68 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe. What is AnaptysBio's official website? The official website for AnaptysBio is www.anaptysbio.com. How can I contact AnaptysBio? AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
